IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PUOTI, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.323
AS - Asia 2.923
EU - Europa 2.208
SA - Sud America 453
AF - Africa 48
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 13
Totale 11.986
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.258
CN - Cina 1.126
SG - Singapore 958
UA - Ucraina 746
DE - Germania 413
BR - Brasile 397
HK - Hong Kong 354
FI - Finlandia 208
IT - Italia 177
GB - Regno Unito 150
TR - Turchia 126
IN - India 118
RU - Federazione Russa 117
IE - Irlanda 114
PL - Polonia 112
VN - Vietnam 96
FR - Francia 51
CA - Canada 41
SE - Svezia 37
BD - Bangladesh 34
ZA - Sudafrica 22
AR - Argentina 20
IQ - Iraq 17
BE - Belgio 16
JP - Giappone 16
MX - Messico 16
AU - Australia 14
EU - Europa 13
NL - Olanda 12
LT - Lituania 11
EC - Ecuador 10
VE - Venezuela 10
AT - Austria 9
IR - Iran 9
PK - Pakistan 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
ES - Italia 8
AE - Emirati Arabi Uniti 6
CO - Colombia 6
IL - Israele 6
MA - Marocco 5
AZ - Azerbaigian 4
ID - Indonesia 4
KE - Kenya 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
BG - Bulgaria 3
CL - Cile 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BY - Bielorussia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
RS - Serbia 2
AO - Angola 1
BF - Burkina Faso 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GY - Guiana 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LR - Liberia 1
LV - Lettonia 1
LY - Libia 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
TM - Turkmenistan 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 11.986
Salva come PNG Salva come JPEG
Città #
Woodbridge 766
Fairfield 665
Ashburn 585
Jacksonville 553
Houston 484
Singapore 451
Hong Kong 354
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 303
Nanjing 228
Princeton 193
Chandler 177
Beijing 169
Dublin 113
Los Angeles 111
Warsaw 111
Istanbul 102
New York 100
Helsinki 92
Nanchang 90
Dearborn 80
Moscow 70
The Dalles 69
Shenyang 59
Des Moines 53
Changsha 48
Munich 47
Buffalo 46
San Diego 46
Shanghai 46
Jinan 43
Tianjin 43
Hebei 41
Ho Chi Minh City 38
São Paulo 38
Jiaxing 36
Lancaster 33
Milan 33
San Francisco 33
Redondo Beach 32
Brescia 30
London 29
Washington 28
Verona 21
Kunming 20
Toronto 18
Brooklyn 17
Hangzhou 17
Brussels 16
Charlotte 16
Chicago 16
Dallas 16
Lanzhou 16
Taizhou 16
Tokyo 16
Kocaeli 15
Rio de Janeiro 15
Santa Clara 15
Zhengzhou 15
Hanoi 14
Guangzhou 13
Leawood 13
San Mateo 13
Brasília 12
Chennai 12
Haikou 11
Johannesburg 11
Monmouth Junction 11
Norwalk 11
Atlanta 10
Augusta 9
Belo Horizonte 9
Delhi 9
Denver 9
Ningbo 9
Porto Alegre 9
Stockholm 9
Ardabil 8
Boston 8
Campinas 8
Melbourne 8
Turku 8
Curitiba 7
Hefei 7
Manchester 7
Nuremberg 7
Orem 7
Tashkent 7
Erbil 6
Mexico City 6
Mumbai 6
Orange 6
Taiyuan 6
Caruaru 5
Caxias do Sul 5
Dhaka 5
Fuzhou 5
Goiânia 5
Totale 8.245
Salva come PNG Salva come JPEG
Nome #
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 181
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 180
Use of brain MRI in manganese exposure 175
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 174
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 166
Antiretroviral drugs and liver injury. 161
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 155
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 154
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 152
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 152
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 150
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 143
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 142
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 141
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 140
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 139
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 139
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 137
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 135
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 135
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 134
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 131
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 129
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 126
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 126
Polymorphic immune restoration syndrome after effective HAART 125
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 124
Care of patients with hepatitis C and HIV co-infection. 121
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 121
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 120
Mortality for liver disease in patients with HIV infection: a cohort study 119
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 118
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 117
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 116
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 114
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 114
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 114
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 113
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 113
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 113
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 112
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 111
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 111
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 109
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 109
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 108
HIV/HCV co-infection: natural history. 108
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 108
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 107
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 106
Natural history of chronic hepatitis B in co-infected patients. 106
The burden of HIV and hepatitis C virus coinfection. 106
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 105
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 105
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 105
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 105
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 105
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 105
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 105
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 104
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 104
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 104
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 104
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 103
Impact of hepatitis C virus infection on lifestyle. 103
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 103
HCV chronic hepatitis in patients with HIV: clinical management issues 102
The use of molecular assays in the management of viral hepatitis. 102
Management of hepatitis C in human immunodeficiency virus-infected patients. 102
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 102
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 102
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 102
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 101
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 101
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 100
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 100
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 100
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 100
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 99
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 99
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 98
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 96
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 96
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 95
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 93
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 92
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 89
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 87
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 86
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 85
HCV infection: pathogenesis, clinical manifestations and therapy. 84
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome 84
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 83
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 81
Risk of developing specific AIDS-defining illnesses in patients coinfected withHIV and hepatitis C virus with or without liver cirrhosis 80
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 77
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 77
Pathogenesis of liver damage in HCV-HIV patients. 75
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 73
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. 72
Totale 11.335
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.559
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021974 0 0 0 0 0 149 82 155 244 110 196 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/20251.702 8 4 7 237 213 158 156 39 150 148 372 210
2025/20261.817 352 484 166 395 382 38 0 0 0 0 0 0
Totale 12.091